BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins

BridgeBio said on Thursday that another of its Phase 3 rare disease studies succeeded, its third in the last few months, setting up a filing with the FDA. The latest win was in children with ...